CardioVascular BioTherapeutics (fka CVBT)

[Beachbum3232]

What I find to be more promising, if I understood CVBT Management correctly, is that the company intends to license out these programs(products) once they are developed successfully. CVBT can make tons of money simply licensing out the products to bigger pharma who would then have the responsibility of commercializing. Maybe in time they launch their own but to launch a drug now a days is very expensive and can be risky when you are talking about a new novel therapy. Market Access and pricing become the biggest issues.